FREMONT, Calif., Sept. 17, 2019 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX), a specialized biopharmaceutical company focused on
developing innovative first-in-class medicines to improve treatment
for people with cardiorenal diseases, today announced that
Mike Raab, president and chief
executive officer of Ardelyx, will present a company overview at
the Ladenburg Thalmann Conference on Tuesday, September 24, 2019 at 9:00 a.m. ET in New
York City.
To access the live webcast of Ardelyx's presentation please
visit the Events & Presentations page within the Investor
section of the Ardelyx website at ir.ardelyx.com. A replay of the
webcast will be available on the Ardelyx website for 60 days
following the conference.
About Ardelyx, Inc.
Ardelyx is focused on enhancing
the lives of people with cardiorenal diseases by developing
first-in-class medicines that matter. Ardelyx's cardiorenal
pipeline includes the Phase 3 development of tenapanor for the
treatment of hyperphosphatemia in people with CKD on dialysis, and
RDX013, a potassium secretagogue program for the potential
treatment of high potassium, or hyperkalemia, a problem among
certain patients with kidney and/or heart disease. On September 3, 2019, the company reported positive
data from AMPLIFY, a pivotal Phase 3 study investigating tenapanor
in a combination with phosphate binders in patients with chronic
kidney disease on dialysis whose hyperphosphatemia was not
previously controlled with binders alone. The study successfully
met the primary endpoint and all key secondary endpoints, including
demonstrating a statistically significant mean reduction in serum
phosphorus from baseline to the end of the treatment period. On
September 12, 2019, Ardelyx received
approval of IBSRELA (tenapanor) for the treatment of irritable
bowel syndrome with constipation (IBS-C). To efficiently bring its
treatments to market, Ardelyx is pursuing strategic collaborations
for IBSRELA for IBS-C and tenapanor for hyperphosphatemia in
certain territories. Ardelyx has established agreements with Kyowa
Kirin Company Limited in Japan,
Fosun Pharma in China and Knight
Therapeutics in Canada. For more
information, please visit http://www.ardelyx.com and connect with
us on Twitter @Ardelyx.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-ladenburg-thalmann-2019-healthcare-conference-300920103.html
SOURCE Ardelyx